Skip to main content
OpenTrials
Completed

NCT Number: NCT04649216

Excretion Balance, PK and Metabolism of a Single Oral Dose of [14C]PCO371

This is a Phase I single center, open-label, non-randomized study in healthy male subjects, designed to evaluate the mass balance recovery, PK, metabolism and absolute bioavailability of single oral doses of PCO371. It is planned to enroll 12 subjects, with 6 subjects in each of 2 study parts. Subjects in Part 1 will receive a single oral dose of [14C]PCO371 Oral Solution. Subjects in Part 2 will receive a single oral dose of PCO371 capsules, followed by a single intravenous infusion of [14C]PCO371 Solution for Infusion over 10 min, starting 2 h post-oral dose. The study parts may be dosed in any order for logistical reasons (e.g. Part 2 may be dosed before Part 1). No subject will be permitted to take part in both study parts.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

40 year–60 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Quotient Sciences

Nottingham, UK, NG11 6JS, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males
  • Aged 40 to 60 years inclusive at the time of signing informed consent.
  • Body mass index (BMI) of 18.5 to 30.0 kg/m2 as measured at screening.
  • Must be willing and able to communicate and participate in the whole study.
  • Subjects must have regular bowel movements (i.e. average stool production of >=1 and <=3 stools per day).
  • Must provide written informed consent.
  • Must agree to adhere to the contraception requirements.
  • Subjects must regularly consume 2 or more units of alcohol per week.

Exclusion criteria

  • Subjects who have taken any experimental (non-approved) drug (including placebo) either within 90 days before the administration of the study drug, or 6 times the T1/2 of the experimental drug, whichever is longer.
  • Subjects who have previously been administered IMP in this study. Subjects are not permitted to be dosed in both Part 1 and Part 2 of the study.
  • Subjects who have been administered IMP in any 14C-labelled ADME in the last 12 months.
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years.
  • No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.
  • Subjects who do not have suitable veins for multiple venipunctures / cannulation as assessed by the investigator or delegate at screening.
  • Clinically significant abnormal clinical chemistry, hematology, coagulation or urinalysis as judged by the investigator at screening or admission.
  • Abnormal (outside of reference range) serum calcium or corrected calcium as measured at admission or screening.
  • Elevated (> 2.5 × upper limit of normal [ULN]) alkaline phosphatase at admission or screening. Subjects with Gilbert's syndrome or elevated (above the ULN) aspartate aminotransferase (AST), ALT or total bilirubin at admission or screening.
  • Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody results.
  • Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <60 mL/min using the Cockcroft-Gault equation.
  • Confirmed positive drugs of abuse test result.
  • History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease, immunologic, metabolism, endocrine, neurological or psychiatric disorder, as judged by the investigator, blood dyscrasia, risk factors for osteosarcoma as judged by the investigator.
  • Evidence or any history of active diseases that might affect calcium, bone metabolism, or calcium-phosphate homeostasis.
  • Use of anti-coagulants (e.g. heparins, warfarin, and thrombolytic agents), anti-platelet medications (e.g. argatroban and ticlopidine), nonsteroidal anti-inflammatory drugs and aspirin within 2 weeks (or within 6 times the T1/2 of the drug, whichever is longer) prior to study drug administration.
  • Subjects who have taken any inducers of CYP3A4, P glycoprotein (e.g. St. John's wort), or BCRP within 1 month prior to study drug administration, or taken any inhibitors of CYP3A4, P-glycoprotein, or BCRP (including herbal products, diets, and drinks e.g. tonic water) within 2 weeks prior to study drug administration (or within 6 times the T1/2 of the drugs mentioned above, whichever is longer).

Treatment and study plan

PCO371

Drug

PCO371 Capsule

[14C]PCO371

Drug

[14C]PCO371 Oral solution

Primary outcomes

  1. Mass balance data for [14C]PCO371 Oral solution in urine

    Time frame: 1 week

    Amount of total radioactivity excreted in urine(Ae(urine)) and Ae(urine) expressed as a percentage of the radioactive dose administered (%Ae(urine)), cumulative amount of total radioactivity excreted in urine (CumAe(urine)) and CumAe(urine)expressed as a percentage of the radioactive dose administered (Cum%Ae(urine)) following oral administration of [14C]PCO371 Oral Solution.

  2. Mass balance data for [14C]PCO371 Oral solution in feces

    Time frame: 5 weeks

    Amount of total radioactivity excreted in feces(Ae(feces)) and Ae(feces) expressed as a percentage of the radioactive dose administered (%Ae(feces)), cumulative amount of total radioactivity excreted in feces (CumAe(feces)) and CumAe(feces)expressed as a percentage of the radioactive dose administered (Cum%Ae(feces)) following oral administration of [14C]PCO371 Oral Solution.

  3. Mass balance data for [14C]PCO371 Oral solution in urine and feces combined

    Time frame: 5 weeks

    Amount of total radioactivity excreted in urine and feces combined(Ae(total)) and Ae(total) expressed as a percentage of the radioactive dose administered (%Ae(total)), cumulative amount of total radioactivity excreted in urine and feces combined (CumAe(total)) and CumAe(total)expressed as a percentage of the radioactive dose administered (Cum%Ae(total)) following oral administration of [14C]PCO371 Oral Solution.

  4. Absolute bioavailability (F) for PCO371

    Time frame: 1 week

    Time of maximum observed concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution

Secondary outcomes

  1. Pharmacokinetic data for [14C]PCO371 Oral Solution; Tmax

    Time frame: 1 week

    Time of maximum observed concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution

  2. Pharmacokinetic data for [14C]PCO371 Oral Solution; Cmax

    Time frame: 1 week

    Maximum observed concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution

  3. Pharmacokinetic data for [14C]PCO371 Oral Solution; AUC(0-last)

    Time frame: 1 week

    Area under the curve from time 0 to the time of last measurable concentration for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution

  4. Pharmacokinetic data for [14C]PCO371 Oral Solution; AUC(0-inf)

    Time frame: 1 week

    Area under the curve from time 0 extrapolated to infinity for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution

  5. Pharmacokinetic data for [14C]PCO371 Oral Solution; T1/2

    Time frame: 1 week

    Terminal elimination half-life for PCO371 and a metabolite in plasma and for total radioactivity in plasma and whole blood following oral administration of [14C]PCO371 Oral Solution

  6. Pharmacokinetic data for [14C]PCO371 Oral Solution; Cmax ratio

    Time frame: 1 week

    Ratio of PCO371: total radioactivity and ratio of a metabolite: total radioactivity based on Cmax following oral administration of [14C]PCO371 Oral Solution

  7. Pharmacokinetic data for [14C]PCO371 Oral Solution; AUC ratio

    Time frame: 1 week

    Ratio of whole blood: plasma total radioactivity based on Cmax following oral administration of [14C]PCO371 Oral Solution

  8. Pharmacokinetic data for [14C]PCO371 Oral Solution; B:P Cmax ratio

    Time frame: 1 week

    Ratio of whole blood:plasma total radioactivity based on Cmax following oral administration of [14C]PCO371 Oral Solution

  9. Pharmacokinetic data for [14C]PCO371 Oral Solution; B:P AUC ratio

    Time frame: 1 week

    Ratio of whole blood:plasma total radioactivity based on AUC following oral administration of [14C]PCO371 Oral Solution

  10. Metabolite profiling of plasma, urine and feces

    Time frame: 1 week

    The chemical structure of each metabolite accounting for >=5% of circulating radioactivity in plasma and accounting for >=5% of the dose in the urine and feces

  11. Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; C0

    Time frame: 1 week

    Concentration at end of infusion of [14C]PCO371 and total radioactivity in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  12. Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; AUC(0-last)

    Time frame: 1 week

    Area under the curve from time 0 to the time of last measurable concentration of [14C]PCO371 and total radioactivity in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  13. Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; AUC(0-inf)

    Time frame: 1 week

    Area under the curve from time 0 extrapolated to infinity of [14C]PCO371 and total radioactivity in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  14. Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; T1/2

    Time frame: 1 week

    Terminal elimination half-life of [14C]PCO371 and total radioactivity in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  15. Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; CL

    Time frame: 1 week

    Total body clearance calculated after a single IV administration of [14C]PCO371 in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  16. Intravenous pharmacokinetic data for [14C]PCO371 Solution for Infusion; Vz

    Time frame: 1 week

    Volume of distribution based on the terminal phase calculated using AUC(0-inf) after a single IV administration of [14C]PCO371 in plasma following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  17. Oral pharmacokinetic data for PCO371 capsule; Tmax

    Time frame: 1 week

    Time of maximum observed concentration for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  18. Oral pharmacokinetic data for PCO371 capsule; Cmax

    Time frame: 1 week

    Maximum observed concentration for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  19. Oral pharmacokinetic data for PCO371 capsule; AUC(0-last)

    Time frame: 1 week

    Area under the curve from time 0 to the time of last measurable concentration for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  20. Oral pharmacokinetic data for PCO371 capsule; AUC(0-inf)

    Time frame: 1 week

    Area under the curve from time 0 extrapolated to infinity for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  21. Oral pharmacokinetic data for PCO371 capsule; T1/2

    Time frame: 1 week

    Terminal elimination half-life for plasma concentration of PCO371 and a metabolite following oral dose of PCO371 capsules and intravenous infusion of [14C]PCO371 Solution for Infusion.

  22. Mass balance data for [14C]PCO371 Solution for Infusion in urine

    Time frame: 1 week

    Cumulative amount of total radioactivity excreted in urine expressed as a percentage of the radioactive dose administered (Cum%Ae(urine)) and cumulative amount of [14C]PCO371 excreted in urine expressed as a percentage of the [14C]PCO371 dose administered (Cum%Ae([14C]PCO371 urine))

  23. Mass balance data for [14C]PCO371 Solution for Infusion in feces

    Time frame: 5 weeks

    Cumulative amount of total radioactivity excreted in feces expressed as a percentage of the radioactive dose administered (Cum%Ae(feces)) and cumulative amount of [14C]PCO371 excreted in feces expressed as a percentage of the [14C]PCO371 dose administered (Cum%Ae([14C]PCO371 feces))

  24. Safety data for PCO371; Adverse event monitoring

    Time frame: 6 weeks

    Incidence and severity of adverse events

  25. Safety data for PCO371; Incidence of laboratory abnormalities

    Time frame: 6 weeks

    Incidence of laboratory abnormalities, based on clinical laboratory tests ( i.e. hematology, clinical chemistry, coagulation and urinalysis test results)

  26. Safety data for PCO371; 12-lead ECGs (Ventricular Rate)

    Time frame: 6 weeks

    Abnormality in Electrocardiograms (ECGs) Interpretation based on Ventricular Rate

  27. Safety data for PCO371; 12-lead ECGs (PR interval)

    Time frame: 6 weeks

    Abnormality in Electrocardiograms (ECGs) Interpretation based on PR interval

  28. Safety data for PCO371; 12-lead ECGs (QRS Duration)

    Time frame: 6 weeks

    Abnormality in Electrocardiograms (ECGs) Interpretation based on QRS Duration

  29. Safety data for PCO371; 12-lead ECGs (QT interval)

    Time frame: 6 weeks

    Abnormality in Electrocardiograms (ECGs) Interpretation based on QT interval

  30. Safety data for PCO371; 12-lead ECGs (QRS Axis)

    Time frame: 6 weeks

    Abnormality in Electrocardiograms (ECGs) Interpretation based on QRS Axis

  31. Safety data for PCO371; 12-lead ECGs (QTcF interval)

    Time frame: 6 weeks

    Abnormality in Electrocardiograms (ECGs) Interpretation based on QTcF interval

  32. Safety data for PCO371; 12-lead ECGs (Rhythm)

    Time frame: 6 weeks

    Abnormality in Electrocardiograms (ECGs) Interpretation based on Rhythm

  33. Safety data for PCO371; Vital signs (Systolic blood pressure)

    Time frame: 6 weeks

    Abnormality in Systolic blood pressure

  34. Safety data for PCO371; Vital signs (Diastolic blood pressure)

    Time frame: 6 weeks

    Abnormality in Diastolic blood pressure

  35. Safety data for PCO371; Vital signs (Heart Rate)

    Time frame: 6 weeks

    Abnormality in Heart Rate

  36. Safety data for PCO371; Vital signs (Oral temperature)

    Time frame: 6 weeks

    Abnormality in Oral temperature

  37. Safety data for PCO371; Presense of abnormalities in Physical examinations

    Time frame: 6 weeks

    Abnormality in Physical examination findings

Sponsors and collaborators

Lead sponsor

Chugai Pharmaceutical

Industry

Registry information

Official study title

A Phase I, Single-Center, Open-Label Study Investigating the Excretion Balance, Pharmacokinetics (PK) and Metabolism of a Single Oral Dose of [14C]PCO371 and PK of an Intravenous (IV) Tracer of [14C]PCO371 in Healthy Male Subjects

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Dec 2, 2020
Registry last updated
Mar 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.